Dosage Regimes in the Prescription of Heroin and Other Narcotics to Chronic Opioid Addicts in Switzerland – Swiss National Cohort Study

Abstract

Aims: Within the guidelines of the research programme on medical prescription of narcotics for opioid addicts (PROVE), heroin, morphine, and methadone were prescribed to heavily opioid addicted individuals in Switzerland since 1994. This contribution analyses the course of dose levels during the treatment period. Design: Naturalistic description of consumed dosages per day and month. Setting and Participants: The study describes the dosages prescribed to all individuals who began outpatient treatment in the PROVE programme in Switzerland between 1994 and 1996. Measurements: Consumed amount of narcotics per day and the course of dosage of injectable heroin in different treatment regimes. Findings: Heroin was the most frequently prescribed narcotic. Of all consumption days, heroin had been applied in 77% as injection and in 9% in a smokeable form. The mean daily dosage was 474 mg for intravenous application and 993 mg for the smokeable form. Second most frequent was the prescription of oral methadone, in most cases in combination with heroin. The mean amount of daily consumption of oral methadone was 53 mg. There were dosage differences between treatment regimes. During the course of treatment the mean dosage for injectable heroin per day decreased significantly and, depending on the treatment regime, almost linearly. Conclusions: The significance of heroin dosages in heroin-assisted therapy for treatment outcome should be further explored, especially in the light of the markedly higher dosages in Switzerland compared to the UK. During the treatment period, dosages did not increase but generally decreased, indicating no further increase in tolerance.

Behavioral economic analysis of opioid consumption in heroin-dependent individuals: Effects of alternative reinforcer magnitude and post-session drug supply

“…First, making supplemental agonist doses readily available to physically dependent patients – creating an open economy by increasing pharmacological (medication) income – can reduce drug seeking. This principle mimics standard opioid substitution therapy, including provision of take-home doses, which function as reinforcers (Amass et al, 1996; Chutuape et al, 1998; Stitzer et al, 1985) and can increase patient retention and reduce drug use (Chutuape et al, 1999; Kidorf et al, 1994; Rhoades et al, 1998), but also medically supervised heroin assisted treatment (Fischer et al, 2002; Gschwend et al, 2004; Rehm et al, 2001). A related issue is that informing patients they can access medication dose increases (e.g.…”

Development and validation of a solid-phase extraction gas chromatography–mass spectrometry method for the simultaneous quantification of methadone, heroin, cocaine and metabolites in sweat

“…We also report—for the first time to the best of our knowledge—the presence of 6AC in the sweat of a heroin user. Maintenance treatment with pharmaceutical-grade heroin is available in Switzerland [32]. 6AC in sweat may offer a unique biomarker of illicit heroin use in patients under treatment with pharmaceutical heroin.…”

Opium for the Masses? Conflict-Induced Narcotics Production in Afghanistan

“…Doses vary a lot, from 1 mg to 5 mg for initial doses to about 1 g for very experienced users. Gschwend et al (2004) report an average daily consumption of 474 mg among heavy users. 27 Since the opium production data are somewhat skewed, see the summary statistics in table 2; we have also run the same regressions as in table 4 with log of opium production as the dependent variable.…”